Story perspectives

Chinese Drug Deals Skyrocket to $135.7 Billion in 2025

1/8/2026

Summary

Story summary

In 2025, Chinese drug makers' out-licensing deals reached 157 agreements worth US$135.7 billion, doubling 94 deals worth US$51.9 billion in 2024, per the National Medical Products Administration (NMPA).
Notable agreements included GeneQuantum's US$13 billion deal with Biohaven Pharmaceutical and AimedBio.
3SBio signed a US$6 billion contract with Pfizer for the SSGJ-707 cancer drug.
These agreements grant exclusive rights for drug development and commercialization in exchange for payments and royalties.

1 of 1

Story summary

In 2025, Chinese drug makers' out-licensing deals reached 157 agreements worth US$135.7 billion, doubling 94 deals worth US$51.9 billion in 2024, per the National Medical Products Administration (NMPA).
Notable agreements included GeneQuantum's US$13 billion deal with Biohaven Pharmaceutical and AimedBio.
3SBio signed a US$6 billion contract with Pfizer for the SSGJ-707 cancer drug.
These agreements grant exclusive rights for drug development and commercialization in exchange for payments and royalties.